

Medicines Optimisation Quarterly Summary Report


Benjamin Spencer

Pharmaceutical Advisor, GP Practice Pharmacist and Joint Pharmacy Lead Old Town Surgery BSW CCG BSW Training Hub



Topics Covered

- The Report
 - Report Overview
 - Financial, Monthly Indicators & Pain
 - Diabetes, Savings and Quality
 - Prescribing Data
 - Special Order Products
 - Potential Generic Savings
 - High-Cost Items
 - Red Drugs
 - Eclipse generated Top 25 savings for your practice
 - Antibiotics by prescriber
- Ideas on how to use the report





The Report

- The Report
 - We organise a quarterly report and send this out to practices, usually to the prescribing lead(s) and Practice Manager
 - Aim of this is to inform prescribing priorities
 - Needs to be put into context
- Organised into sections
 - Prescribing Performance Summary
 - Prescribing Data to Review (Last Quarter)
 - Specials, Savings, high Cost Items, red drug and NHSE low value medicine reports
 - Eclipse generated top 25 savings
 - Antibiotics by prescriber



Medicines Optimisation Quarterly Summary Report

OLD TOWN SURGERY

To inform prescribing priorities Data from October to December 2020 Quarter 3

Right Medicine- Right Time






Report Overview

	Indicators		Period	OLD TOWN SURGERY	BSW CCG	Nation
inancial	Actual Cost per Astro PU	All BNF Chapters ctual cost per 1,000 ASTRO PU	Oct to Dec 2020	£9,237.32	£9,510.35	£10,776
thly	CoAmoxiclav, Quinolones & Cephalosporins	% of Cephalosporin, Co Amoxiclav & Quinolones items of all antibacterial items	Rolling 12 months	13.73%	10.61%	9.439
Monthly Indicators	Antibacterial Items/STAR PU	BNF 5.1 Total Antibacterial ITEMS/STAR-PU	Jan to Dec 2020	0.70	0.77	0.81
	Pain - Opiod Prescribing	ADQ/1000 STAR PU]	358	318	366
	Gabapentin/Pregabalin	BNF 3.1 ADQ/STAR PU		0.24	0.20	0.22
Pain	Tramadol	ADQ per Analgesics STAR PU	Q3 - 20/21	0.090	0.099	0.09
Ъ	NSAIDs	BNF 10.1.1 ADQ/STAR PU	Oct - Dec 2020	1.25	1.16	1.00
	NSAIDs 2	Ibuprofen & naproxen % items]	72.10%	80.05%	78.95
y	Diabetes Cost per ASTRO PU Self Monitoring Blood Glucose Strips % of low cost	BNF 6.1 Total Cost per ASTRO PU	03 - 20/21 Oct - Dec 2020	£1,141.49	£1,148.07	£1,337
ator	items	Low cost items <£10		54.88%	70.20%	77.14
ğ	Gliptins	Cost per ASTRO PU		£141.61	£165.11	£245
Diabetes Indicators	% Analogue Insulins (Long acting)	Long/intermediate insulin analogues items Glargines, Detamir & Degludec		94.12%	78.41%	80.40
)iab	% Metformin MR Items	% MR, SR and XL Items of BNF 6.1.22B0		56.51%	33.78%	16.17
_	% Alogliptin	% Alogliptin of all Gliptins		27.45%	37.23%	24.39
		, ,				
	Sip Feeds	Cost per 1000 ASTRO PU		£180.26	£141.19	£198.
	Selfcare Cost	Monthly Average per 1000 patients	1	£541.10	£635.87	£716.
	% Edoxaban	% Edoxaban of all DOACs	1	7.49%	15.34%	11.93
ators	% Generic Savings	Potential generic savings	Q3 - 20/21	68.39%	48.92%	46.80
ğ	OAB Drugs	Cost per 1000 ASTRO PU	Oct - Dec 2020	£108.82	£110.58	£116.
Savings Indicators	Less preferred Lipid Treatments	(Omega 3 acid esters, Nicotinic acid, Bile acid sequesterents) Cost per STAR PU		£0.00	£12.93	£16.0
Sav	% Sildenafil and Tadalafil of all 5PDI items	% Sildenafil and Tadalafil Items of all Phosphodiesterase type -5 Inhibitors		98.40%	91.97%	90.65
	·			<u> </u>		
r.	Hypnotics	BNF 4.1.1 ADQ/STAR PU		0.33	0.18	0.17
ato	Specials Cost	Cost per ASTRO PU Special Order & Drug Tariff combined		£3.29	£23.85	£46.5
ngi Si	Stoma Products	Cost per 1000 ASTRO PU	Q3 - 20/21	£306.32	£358.82	£373.
Quality Indicators	% DOACs of all OAC items	% DOACs of all Anti-Coagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)	Oct - Dec 2020	69.77%	79.59%	72.14
õ	Proton Pump Inhibitors	ADQ per STAR PU	1	5.04	5.17	5.48



Prescribing Data

• Gives you an indication of how your prescribing costs for your practice compare to other practices across BSW CCG but also on a national level.





Special Order Products

- A list of special order products prescribed by your practice
- Were there any licensed or off-label options available
- If you're not sure what alternative are available, information can be found in the NEWT guidelines or Handbook of Drug Administration Via Enteral Feeding Tubes

Total Actual Cost:	£97
--------------------	-----

BNF Name	Supplier	Total Items	Total Actual Cost
Carbimazole 10mg/5ml oral suspension	Drug Tariff Special Order	1	£80.21
Bisoprolol 2.5mg/5ml oral solution	Drug Tariff Special Order	1	£16.54



Potential Generic Savings

Potential Generic savings/quarter Q3 (October to December 2020)

Total Practice Cost: £252,581.55 Potential Saving: 0.76%

Proprietary	Generic	Items	QTY	Prop.Cost	Gen.Cost	Potential Savings £
Cymbalta 60mg gastro-resistant capsules (0403040Y0BBABAB)	Duloxetine 60mg gastro-resistant capsules	2	224	£221.76	£18.88	£202.88
Cerazette 75microgram tablets (0703021Q0BBAAAA)	Desogestrel 75microgram tablets (0703021Q0AAAAAA)	17	2212	£251.48	£75.31	£176.17
Zyprexa 10mg tablets (040201060BBACAC)	Olanzapine 10mg tablets (040201060AAACAC)	1	56	£174.80	£5.40	£169.40
Zomig Rapimelt 2.5mg orodispersible tablets (0407041Z0BBABAB)	Zolmitriptan 2.5mg orodispersible tablets sugar free	1	48	£191.92	£83.84	£108.08
Combodart 0.5mg/0.4mg capsules (0704010V0BBAAAA)	Tamsulosin 400microgram / Dutasteride 500microgram	4	240	£158.40	£53.68	£104.72
Lipitor 40mg tablets (0212000B0BBACAC)	Atorvastatin 40mg tablets (0212000B0AAACAC)	4	112	£98.56	£5.68	£92.88
Imigran 50mg tablets (0407041T0BBAFAF)	Sumatriptan 50mg tablets (0407041T0AAAFAF)	3	18	£95.55	£4.20	£91.35
Lustral 100mg tablets (0403030Q0BBABAB)	Sertraline 100mg tablets (0403030Q0AAABAB)	2	112	£116.64	£35.52	£81.12
Lipitor 80mg tablets (0212000B0BBADAD)	Atorvastatin 80mg tablets (0212000B0AAADAD)	1	84	£84.63	£6.09	£78.54
Singulair 10mg tablets (0303020G0BBABAB)	Montelukast 10mg tablets (0303020G0AAABAB)	3	84	£80.91	£7.62	£73.29
Ezetrol 10mg tablets (0212000L0BBAAAA)	Ezetimibe 10mg tablets (0212000L0AAAAAA)	1	84	£78.93	£7.53	£71.40
Lipitor 20mg tablets (0212000B0BBABAB)	Atorvastatin 20mg tablets (0212000B0AAABAB)	1	84	£73.92	£4.20	£69.72
Nexium 40mg gastro-resistant tablets (AstraZeneca) (0103050E0BBABAB)	Esomeprazole 40mg gastro-resistant tablets	1	84	£75.57	£12.00	£63.57
Cosopt 20mg/ml / 5mg/ml eye drops (1106000ABBBAAAA)	Dorzolamide 20mg/ml / Timolol 5mg/ml eye drops	3	30	£60.30	£14.64	£45.66
Mirapexin 0.088mg tablets (0409010W0BBACAC)	Pramipexole 88microgram tablets	3	168	£62.94	£20.10	£42.84
Spasmonal Forte 120mg capsules (0102000A0BBABAB)	Alverine 120mg capsules (0102000A0AAABAB)	2	252	£81.57	£38.98	£42.59
Movicol Plain oral powder 13.7g sachets (0106040M0BBADAA)	Macrogol compound oral powder sachets NPF sugar	6	344	£92.97	£50.69	£42.28
Azopt 10mg/ml eye drops (1106000ACBBAAAA)	Brinzolamide 10mg/ml eye drops (1106000ACAAAAAA)	13	70	£96.88	£55.86	£41.02
Seroxat 20mg tablets (0403030P0BBAAAA)	Paroxetine 20mg tablets (0403030P0AAAAAA)	3	90	£45.69	£5.22	£40.47
Movicol oral powder 13.8g sachets lemon & lime (0106040M0BBAAAA)	Macrogol compound oral powder sachets NPF sugar	7	260	£70.22	£38.32	£31.90
Cerelle 75microgram tablets (0703021Q0BDAAAA)	Desogestrel 75microgram tablets (0703021Q0AAAAAA)	34	4032	£168.02	£137.28	£30.74
Neoclarityn 5mg tablets (0304010ABBBAAAA)	Desloratadine 5mg tablets (0304010ABAAAAAA)	3	180	£40.62	£10.62	£30.00
Ursofalk 250mg capsules (0109010U0BCAAAB)	Ursodeoxycholic acid 250mg capsules	3	252	£80.34	£52.84	£27.50
Pariet 10mg gastro-resistant tablets (0103050T0BBAAAA)	Rabeprazole 10mg gastro-resistant tablets	2	168	£34.68	£9.12	£25.56
Travatan 40micrograms/ml eye drops (1106000AEBBAAAA)	Travoprost 40micrograms/ml eye drops	3	7.5	£32.85	£7.59	£25.26
Nasonex 50micrograms/dose nasal spray (1202010U0BBAAAA)	Mometasone 50micrograms/dose nasal spray	7	8	£61.44	£36.96	£24.48
Zimovane 7.5mg tablets (0401010Z0BBAAAA)	Zopiclone 7.5mg tablets (0401010Z0AAAAAA)	20	336	£39.20	£15.12	£24.08
Movicol Chocolate oral powder 13.9g sachets (0106040M0BBAEAA)	Macrogol compound oral powder sachets NPF sugar	3	168	£45.42	£24.75	£20.67
Xalacom eye drops (1106000ADBBAAAA)	Latanoprost 50micrograms/ml / Timolol 5mg/ml eye	2	5	£28.64	£10.60	£18.04
Emozul 40mg gastro-resistant capsules (0103050E0BCABAG)	Esomeprazole 40mg gastro-resistant capsules	2	112	£25.48	£13.44	£12.04



High-Cost Items

- It might be worth reviewing this list, are there any cheaper alternatives.
- Is there anything on the list which shouldn't be prescribed in primary care?

High cost items (>£250/item) Q3 (October to December 2020)

Total Actual Cost: £11,029.88

BNF Name	Actual Cost Per Item	Total Items	Total Actual Cost
PKU Maxamum powder orange	£1,013.59	3	£3,040.76
NutropinAq 10mg/2ml solution for injection cartridges	£566.44	3	£1,699.32
HydroSil gripper catheter male 10Ch-18Ch	£519.53	2	£1,039.06
Peristeen anal irrigation system accessory unit	£508.24	1	£508.24
Neoral 100mg capsules	£380.31	1	£380.31
Omeprazole 10mg/5ml oral suspension sugar free	£342.25	1	£342.25
Levothyroxine sodium 100micrograms/5ml soln sugar free	£306.88	1	£306.88
Colomycin 1million unit inj vials	£301.32	1	£301.32
iQ Cath integrated saline sachet hydrophilic catheter male 10Ch-18Ch	£274.14	5	£1,370.70
SenSura Soft Seal convex ileo bag with dual filter, Hide-Away outlet and split cover, maxi 15-33mm	£261.91	2	£523.83
SenSura colostomy bag with dual filter, maxi 10-65/76mm transparent	£254.25	3	£762.74
Confidence Natural colostomy bag with filter and overlap, standard 38mm	£253.52	1	£253.52
Pelican Platinum with Vitamin E colostomy bag with filter, standard 35mm clear	£250.73	1	£250.73
Pelican Platinum with Vitamin E colostomy bag with filter, standard 40mm clear	£250.22	1	£250.22

Red Drugs

- "Red Drugs" as we know are for specialist prescribing only, and shouldn't be prescribed in primary care
- Agomelatine no longer a 'Red Drug', is now non-formulary, patient has tried all other options, under MHT
- Same with Dermamist

Red Drugs Q3 (October to December 2020) (NB. Currently being updated, may not be completely accurate)

Total Actual Cost: £117.88

BNF Name	Total Actual Cost Total I	tems
Agomelatine 25mg tablets	£112.33 2	
Dermamist 10% spray	£5.55 1	



Items of low clinical value

Items of Low Clinical Value (NHSE) - All Items Q3 (October to December 2020)

Total Actual Cost: £3,796.38

DAIE No.	la	Net Ingredient	Actual Cost	No. of Identifiable
BNF Name	Items	Cost	Actual Cost	Patients
Amiodarone [NEW 2019]	6	£22.14	£20.65	4
Bath and shower preparations for dry and pruritic skin conditions [NEW 2019]	16	£130.11	£121.19	11
Dosulepin	21	£383.22	£356.86	7
Immediate Release Fentanyl	13	£2,724.54	£2,533.94	1
Lidocaine Plasters	5	£362.00	£336.48	2
Minocycline for acne [NEW 2019]	3	£57.22	£53.46	2
Needles five pounds or more per 100 [NEW 2019]	17	£271.23	£252.27	10
Paracetamol and Tramadol Combination Product	2	£19.36	£18.03	1
Perindopril Arginine	1	£31.95	£29.72	1
Prolonged-release Doxazosin	3	£29.96	£27.89	1
Travel Vaccines	4	£49.36	£45.88	1



Items of low clinical value

Useful Links

Prescribing Guidelines	<u>Shared</u> <u>Care Agreements</u>	BSW Management of Infections in Primary Care Full Guideline Quick Ref Guide adults Quick Ref Guide children
BSW CCG Medicines Optimisation Website	BSW Area Prescribing Committee & High Cost Drugs website	AWP formulary and AWP prescribing guidance
COVID - NHSE Covid Guidance for HCPs	COVID - BSWCCG MMT Covid Guidance for HCPs	COVID - Local BSWCCG guidance for members of the public
BSW formulary Palliative Care Chapter	End Of Life Prescribing Guidance during COVID- 19 outbreak	BSW Community Pharmacy Emergency Drugs List & Contact Details
BSW Continence and Stoma Information	BSW Wound Care and Dressings Information	BSW Primary Care Prescribe Well Spend Less
Royal United Hospitals Bath NHS Foundation Trust <u>intranet link</u>	Great Western Hospitals NHS Foundation Trust <u>intranet</u> <u>link</u>	Salisbury NHS Foundation Trust <u>intranet</u> <u>link</u>
BaNES Community H&C Services <u>VirginCare intranet link</u>		

Category	Recommendation (See SystmOne TPP searches under Meds Management Reporting)	FROM	то	SAVING per PATIENT per YEAR	Link to MMT website statement
	Avoid sodium cromoglicate eye drops – other eye drops available	Sodium cromoglicate eye drops	Consider olopatadine eye drops. (Rapitil discontinued)	£5 per bottle	Large price increase – 13.5ml now costs £12.5
6. NHSE Low Value	Avoid prescribing - poor NHS value	Dicycloverine (any dose and formulation)	Mebeverine, Hyoscine, Alverine, Mintec	Up to £1,968	
Medicines (LVM)	STOP prescribing	Co-Proxamol	Paracetamol +/- weak opioid	Up to £1,937 depending on usage	NHSE Low Value Medicine Co-proxamol NHSE Low Value Medicines Blacklist
	STOP prescribing once daily tadalafil (Cialis) (Guidance still valid even with changes in pricing; generic 5mg reduced to £6.87 but 2.5mg cost unchanged @ £54.99/28)	Cialis OD (2.5mg or 5mg)	Sildenafil or Tadalafil (once a week or on demand PRN)	£676 (if brand)	ED statement NHSE Low Value Medicines Do not prescribe
	Prescribe as separate ingredients	Tramacet	Tramadol & Paracetamol	£70	NHSE Low Value
	Avoid prescribing combination - LVM	Targinact (oxycodone & naloxone)	Opioid & separate laxative	£500	Medicines Do not prescribe
	Swap to alternative	Trimipramine	Alternative antidepressant	£4000	NHSE Low Value Medicines Trimipramin
	Swap to alternative	Dosulepin	Alternative antidepressant. SAFETY ISSUE	£200 if on 75mg tabs	& <u>Dosulepin</u> (includes patient information and letter)
	No new initiations, stop	Lidocaine patches	If can't be stopped, prescribe Ralvo brand	£868	NHSE Low Value Medicines Do not prescribe
-Care/OTC	Stop eyelid hygiene products	Blephasol, Blephagel, Blephaclean	Stop or purchase OTC	Up to £50	Blepharitis
			Purchase OTC (or swop to Fenbid (ibuprofen) if appropriate)	Up to £50 depending on use	NHSE Low Value Medicines Do not prescribe



Eclipse generated Top 25 savings for your practice

Eclipse generated top 25 savings for your practice (annualised cost saving)

Potential Savings for 12 months [Review data: November 2020 - January 2021]	Cost saving
Fentanyl Oral (Abstral Sublingual Tablet) 100 mcg unit tab Pack of 30 -> No Prescribing 1 N/A N/A Pack of 1 [Ratio 0.03:1]	£11,354
Fluticasone / Salmeterol MDI (Seretide Evohaler) 125 /25mcg (120 dose unit) Pack of 1 -> Salmeterol / Fluticasone inhaler (AirFluSal) 25 mcg dose / 125mcgs 120d CFC free PMDI Pack of 1 [Ratio 1.00:1]	£3,177
Dosulepin (Dothiepin) 75 mg Tab Pack of 28 -> No Prescribing 1 N/A N/A Pack of 1 [Ratio 0.04:1]	£1,839
Budesonide/ Formoterol (Symbicort Turbohaler) 200 / 6mcg (120 dose unit) Pack of 1 -> Budesonide / Formoterol (Fobumix Easyhaler) 160 mcg/dose / 4.5mcg/dose dry powder inhaler (120 D) Pack of 1 [Ratio 1.00:1]	£1,716
Olanzapine (Zyprexa) 10 mg tab Pack of 28 -> Olanzapine 10 mg tab Pack of 28 [Ratio 1.00:1]	£1,359
Fluticasone / Salmeterol MDI (Seretide Evohaler) 250 /25mcg (120 dose unit) Pack of 1 -> Salmeterol / Fluticasone inhaler (AirFluSal) 25 mcg dose / 250mcgs 120d CFC free PMDI Pack of 1 [Ratio 1.00:1]	£1,337
Sodium hyaluronate 0.2% eye drops preservative free (Hylo-Forte) 0.2 % eye drops (10 ml unit) Pack of 1 -> Sodium hyaluronate (HydraMed) 0.2 % eye drops 10ml unit dose pf Pack of 1 [Ratio 1.00:1]	£1,326
Glucose Test Strips (Accu-Chek Aviva) 50 Test Strips Pack of 50 -> Blood Glucose colorimetric cassette (Accu-Chek Mobile) 50 device Pack of 50 [Ratio 1.00:1]	£1,194
Naproxen 500 mg E/C tab Pack of 56 -> Naproxen 500 mg tab Pack of 28 [Ratio 0.50:1]	£1,190
Budesonide/ Formoterol (Symbicort Turbohaler) 400 / 12mcg (60 dose unit) Pack of 1 -> Budesonide / Formoterol (Fobumix Easyhaler) 320 mcg/dose / 9mcg/dose dry powder inhaler (60 D) Pack of 1 [Ratio 1.00:1]	£1,170
Trandolapril 4 mg caps Pack of 28 -> Trandolapril 2 mg caps Pack of 28 [Ratio 0.50:1]	£1,143
Orlistat 120 mg caps Pack of 84 -> No Prescribing 1 N/A N/A Pack of 1 [Ratio 0.01:1]	£1,142
Pregabalin (Lyrica) 25 mg cap Pack of 56 -> Pregabalin 25 mg cap Pack of 56 [Ratio 1.00:1]	£1,123
Amitriptyline Solution 10 mg/5mls Solution Pack of 150 -> Amitriptyline 10 mg tab Pack of 28 [Ratio 0.19:1]	£1,045
Fluoxetine 10 mg cap Pack of 30 -> Fluoxetine (Olena) 20 mg dispersable tablets Pack of 28 [Ratio 1.87:1]	£996
Desogestrel (Cerazette) 75 mcg tab Pack of 84 -> Desogestrel 75 mcg tab Pack of 84 [Ratio 1.00:1]	£834



Ideas on how to use the report

- I discuss the report at our quarterly 'Clinical Meeting' for our clinicians
- I have a slot in this meeting to discuss 'prescribing'
- We agree to focus on priority areas in line with our current capacity
- Always celebrate things you do well as a practice (we've recently turned 'GREEN' for tramadol after some remedial action)
- We agreed as a team to investigate <u>Antibiotics, NSAIDs (NSAID 2), and Hypnotic prescribing</u>
- This is all documented in minutes so we can follow up in the next quarterly meeting and keep as evidence for CQC

	Indicators		Period	OLD TOWN SURGERY	BSW CCG	National
Financial	nancial Actual Cost per Astro PU All BNF Chapters ctual cost per 1,000 ASTRO PU		Oct to Dec 2020	£9,237.32	£9,510.35	£10,776.47
onthly	CoAmoxiclav, Quinolones & Cephalosporins	% of Cephalosporin, Co Amoxiclav & Quinolones items of all antibacterial items	Rolling 12 months	13.73%	10.61%	9.43%
Mont	Antibacterial Items/STAR PU	BNF 5.1 Total Antibacterial ITEMS/STAR-PU	Jan to Dec 2020	0.70	0.77	0.81
2 2	Pain - Opiod Prescribing	ADQ/1000 STAR PU		358	318	366
		·				
	Gabapentin/Pregabalin	BNF 3.1 ADQ/STAR PU		0.24	0.20	0.22
Pain	Tramadol	ADQ per Analgesics STAR PU	Q3 - 20/21	0.090	0.099	0.097
Ра	NSAIDs	BNF 10.1.1 ADQ/STAR PU	Oct - Dec 2020	1.25	1.16	1.00
	NSAIDs 2	Ibuprofen & naproxen % items		72.10%	80.05%	78.95%



Co-amoxiclav, Quinolones & Cephalosporin


- Total Antibiotics are under the local and national average GOOD
- However broad-spectrum antibiotics are higher than local and national average BAD
- The question is Are we prescribing inappropriately?
 - Or is it because we prescribe less antibiotics, that a greater proportion of what we do prescribe are broad-spectrum antibiotics – Wishful thinking?
- We need to audit whether we followed our local guidelines

	Indicators		Period	OLD TOWN SURGERY	BSW CCG	National
Financial	Actual Cost per Astro PU	All BNF Chapters ctual cost per 1,000 ASTRO PU	Oct to Dec 2020	£9,237.32	£9,510.35	£10,776.47
Monthly Indicators	CoAmoxiclav, Quinolones & Cephalosporins	% of Cephalosporin, Co Amoxiclav & Quinolones items of all antibacterial items	Rolling 12 months	13.73%	10.61%	9.43%
dica	Antibacterial Items/STAR PU	BNF 5.1 Total Antibacterial ITEMS/STAR-PU	Jan to Dec 2020	0.70	0.77	0.81
2 5	Pain - Opiod Prescribing	ADQ/1000 STAR PU		358	318	366



Co-amoxiclav, Quinolones & Cephalosporins

- Look to see whether a search already exist in your 'reporting'
- Ardens sometimes build searches for their templates and might to a good starting point.
- Or build your own searches? Can someone at your PCN help with if you don't know how






Co-amoxiclav, Quinolones & Cephalosporins

- We decided to review the last 28 days prescriptions for Co-amoxiclav, Quinolones & Cephalosporin
- We constructed a table as below, and recorded
 - Indication
 - Whether it was initiated by primary or secondary care
 - Was the choice in line with current guidelines

Surname	First Name	Antibiotic	Date Prescribed	Indication	Primary or Secondary care	In line with guidelines (Y/N
	Surname	Surname First Name	Surname First Name Antibiotic	Surname First Name Antibiotic Date Prescribed	Surname First Name Antibiotic Date Prescribed Indication	Surname First Name Antibiotic Date Prescribed Indication Secondary care



Co-amoxiclav, Quinolones & Cephalosporins



Antibiotic		Adult Dose (oral unless otherwise stated)	Length	Antibiotic		Adult Dose (oral unless otherwise stated)	Lengti		
Upper Respiratory Tract Infections Treating your infection-RTI PIL RCGP					If risk of resistance (or seek micro advice) Co-amoxiclav 625mg TDS 7-14 days				
Influenza: PHE Influer	nza NICE Influenza (pro	phylaxis)				stridium difficile PHE See full guidance for a	antibiotic option		
		PPAIN Avoid antibiotics where possible			rticulitis NICE NG147 2019 ering antibiotics if the patient is	systemically unwell.			
1 st choice	Penicillin V	500mg QDS OR 1g BD	5-10 days	1 st line:	Co-amoxiclav	500/125mg TDS)		
Penicillin allergy	Clarithromycin	250mg BD OR 500mg BD if severe	5 days	If penicillin	Cefalexin 500mg* BD or TDS AND Metronidazole 400mg TDS *Up to 1-1.5g TDS or QDS can be used for severe infection.		5 days		
Pregnant + allergy	Erythromycin	250-500mg QDS or 500mg-1g BD	5 days	allergy	' ' '	onger course may be needed base on clinical assessment			
Acute Otitis Externa	CKS OE Use analge	sia as well. <mark>For topical 1st line treatments- see ful</mark>	l guideline		_ ,	ND Metronidazole 400mg TDS	- 		
If cellulitis	Flucloxacillin 250mg QDS OR 500mg QDS if severe 7 days			Urinary Tr	ract Infections: Encourage	hydration. Culture in all treatment failure	es and patients		
Acute Rhinosinusitis	NICE RTIS NICE sine	usitis Avoid antibiotics if possible, Use adequate a	nalgesia first	increased re		net and consider risks for resistance. Give \underline{T}	ARGET UTI PIL ar		
1 st choice	Penicillin V	500mg QDS	5 days			nce algorithm for diagnosis information			
Penicillin allergy	Doxycycline OR	200mg 1st dose then 100mg once daily	5 days	Uncomplica	ted UTI: PHE URINE, RCGP U	TI clinical module			
	Clarithromycin	500mg BD (Erythromycin 250mg to 500mg QDS if pregnant)	5 days		rofurantoin 100mg m/r BD of resistance: Trimethoprim 20	R if unavailable Nitrofurantoin 50mg QDS Omg BD			
Unwell/worsening	Co-amoxiclav	625mg TDS	5 days	If 1 st line or	tions unsuitable:		7 days men		
Lower Persirator	Tract Infections:	Treating your infection-RTI PIL RCGP		If eGFR<45i		gic: Pivmecillinam (400mg 1 st dose then	3 days women		
Lower Respiratory									
	chitis NICE NG120 NI	CE 69 RCGP CKS Further treatment options in full guid	dance			rgy: Fosfomycin 3g STAT in women. In men	1		



Co-amoxiclav, Quinolones and& Cephalosporins

- Analyse the results
- How often did your practice prescribe outside of guidance recommendation
- Was it the same clinician
- Is there a pattern with respect to the condition being prescribed for

Results:

- 1 GP prescribed Co-amoxiclav 5 times outside of the guidelines.
- Another GP prescribe Ciprofloxacin once outside of the guidelines
- I fed back the results at the next scheduled Clinical Meeting and we agreed the following actions:
- To organise an update for all clinicians on the antibiotic's guidelines focusing on the common indications which came up in the audit
- We also provided a laminated copy of the antibiotic's guidelines in each of the clinicians' rooms
- Monitor quarterly report and reaudit in 3-6 months



- Our NSAIDs 2 indicator tells us we are prescribing more options which are not first line compared to other local practices and also nationally
- The question is Are we prescribing inappropriately?
- Have we tried all the first line options?

		_			
Gabapentin/Pregabalin	BNF 3.1 ADQ/STAR PU		0.24	0.20	0.22
Tramadol	ADQ per Analgesics STAR PU	Q3 - 20/21 Oct - Dec 2020	0.090	0.099	0.097
NSAIDs	BNF 10.1.1 ADQ/STAR PU		1.25	1.16	1.00
NSAIDs 2	Ibuprofen & naproxen % items		72.10%	80.05%	78.95%
	Tramadol	Tramadol ADQ per Analgesics STAR PU NSAIDs BNF 10.1.1 ADQ/STAR PU	Tramadol ADQ per Analgesics STAR PU Q3 - 20/21 NSAIDs BNF 10.1.1 ADQ/STAR PU Oct - Dec 2020	Tramadol ADQ per Analgesics STAR PU Q3 - 20/21 0.090 NSAIDs BNF 10.1.1 ADQ/STAR PU Oct - Dec 2020 1.25	Tramadol ADQ per Analgesics STAR PU Q3 - 20/21 0.090 0.099 NSAIDs BNF 10.1.1 ADQ/STAR PU Oct - Dec 2020 1.25 1.16





- Ardens have some searches for NSAIDs
- They have one for NSAIDs All minus Ibuprofen and naproxen (oral)


Pharmacist Monitoring - NSAID risk assessments last month Pharmacist Monitoring - NSAID risk assessments last year Pharmacist Monitoring - NSAID risk assessments last month Pharmacist - NSAID risk assessments last year with code Pharmacist - NSAID risk assessments last month with code	0	0.0 %
NSAIDs - On repeat - Naproxen (oral)	99	1.1 %
NSAIDs - On repeat - Ibuprofen or naproxen (oral)	126	1.4 %
NSAIDs - On repeat - Ibuprofen (oral)	28	0.3 %
NSAIDs - On repeat - Diclofenac (all)	6	0.1 %
NSAIDs - On repeat - All minus Ibuprofen and naproxen (oral)	57	0.6 %
NSAIDs - On repeat - All and age >65y		
NSAIDs - On repeat - All	183	2.0 %
NSAIDs - On repeat - All	204	2.3 %
NSAIDs - Naproxen (oral)	83	0.9 %
NSAIDs - Ibuprofen or naproxen (oral)	122	1.4 %
NSAIDs - Ibuprofen (oral)	39	0.4 %
NSAIDs - GI risk factors	3948	43.6 %




- We decided to review notes of all patients who have an NSAID on repeat (not Naproxen/Ibuprofen)
- We constructed a table as below, and recorded
 - Whether it was initiated by primary or secondary care
 - Previously tried Naproxen/Ibuprofen
 - Naproxen/Ibuprofen suitable? (GI risk)
- Arranged telephone reviews with individual patients to discuss their NSAID if not first line, and no evidence previously being prescribed this.

NHS No.	Surname	First Name	Antibiotic	Date Prescribed	Primary or Secondary care	Previously tried Naproxen/Ibuprof en	Naproxen/Ibuprof en unsuitable










- We're currently 2x the national average
- Are we prescribing inappropriately?
- What's our practice policy on initiating dependency forming medication, do we need one?

ť	Hypnotics	BNF 4.1.1 ADQ/STAR PU		0.33	0.18	0.17
ato	Specials Cost Stoma Products % DOACs of all OAC Items	Cost per ASTRO PU Special Order & Drug Tariff combined		15.29	£23.85	£46.52
B		Cost per 1000 ASTRO PU	Q3 - 20/21	£306.32	£358.82	£373.33
tallty		% DOACs of all Anti-Coagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)	Oct - Dec 2020	69.77%	79.59%	72.14%
ð	Proton Pump Inhibitors	ADQ per STAR PU		5.04	5.17	5.48



- Ardens have some searches for Hypnotics
- We decided to run these, and see how many patients had hypnotics on repeat





- We analysed the results, and it showed 86 patients had hypnotics on repeat
- NICE guidelines suggest for short term use only,
 - Pharmacological therapy should be avoided in the long-term management of insomnia, however:
 - For some people with severe symptoms or an acute exacerbation a short course of a hypnotic drug (preferably less than 1 week) may be considered as a temporary adjunct to behavioural and cognitive treatment.

Insomnia (short-term use)

By mouth

For Adult

7.5 mg once daily for up to 4 weeks, dose to be taken at bedtime.

For Elderly

Initially 3.75 mg once daily for up to 4 weeks, dose to be taken at bedtime, increased if necessary to 7.5 mg daily.



- I decided to do a bit of 'research!'
 - Cormack et al, 1994: Paper on cost-effective strategies for reducing benzodiazepines in general practice.
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1238754/
 - Mugunthan et al., 2011: A meta-analysis showing that letter-only intervention can be effective in reducing benzodiazepine prescribing, no evidence to suggest follow up consultations offer any additional support https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162180/
 - NHS, sleep hygiene advice for patients

https://www.nhs.uk/live-well/sleep-and-tiredness/how-to-get-to-sleep/



 Cormack et al, 1994: Paper on cost-effective strategies for reducing benzodiazepines in general practice.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1238754/

ORIGINAL PAPERS

Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice

MARGARET A CORMACK KIERAN G SWEENEY HELEN HUGHES-JONES GEORGE A FOOT

SUMMARY

Aim. This study set out to assess the effect of a letter from the general practitioner, suggesting a reduction in the use of benzodiazepines, and whether the impact of the letter could be increased by the addition of information on how to tackle drug reduction.

Method. Two hundred and nine long-term users of benzodiazepines in general practice were divided into three groups: two intervention groups and a control group. The first intervention group received a letter from their general practitioner asking that benzodiazepine use be gradually reduced and perhaps, in time, stopped. The second intervention group received the same letter plus four information sheets at monthly intervals, designed to assist drug reduction. The mean age of the 209 people was 69 years (age range 34-102 years).

Results. After six months, both intervention groups had reduced their consumption to approximately two thirds of the original intake of henzodiazenines and there was a sta-

For over 10 years general practitioners have received clear advice about the problems associated with prescribing benzodiazepines.⁵⁻⁷ Evidence continues to accumulate that benzodiazepines impair performance, including driving,⁸⁻⁹ they affect the memory ¹⁰ and have adverse cognitive effects.¹¹ The *British national formulary* states that hypnotic drugs should be avoided in elderly people, owing to the risks of ataxia and confusion.

A number of studies have assessed the effect of various interventions to reduce the consumption of benzodiazepines. Interventions such as anxiety management, counselling or cognitive therapy have been shown to reduce drug taking. 12-15 Cormack and Sinnott found that a letter from the prescribing general practitioner, advising patients to cut down on their drugs, was as effective as a group run by a psychologist. 16 In a later, controlled study, a similar intervention was found to be as effective as a short consultation with the general practitioner. 17 Both these studies of the effect of a letter from the general practitioner had comparatively small samples of patients, thus limiting the generalizability of the findings. This study, carried out in 1989 and 1990, attempts to assess the effect of such a letter from the prescribing general practitioner to long-term users of benzodiazepines, using a larger sample from the combined populations of three group practices. The effect of the letter is compared with that of a more complex intervention (a series of information sheets) and with the results from a control group who received no intervention.

M A Cormack, K G Sweeney, H Hughes-Jones and G A Foot

Original papers

reduce drug consumption, then there would be a substantial reduction in the morbidity associated with their side effects, as well as a considerable saving in the drugs bill.

Appendix 1. Letter from general practitioner received by intervention groups.

Dear .

I am writing to you because I note from our records that your have been taking... for some time now. Recently, family doctors have become concerned about this kind of tranquillizing medication when it it taken over long periods. Our concern is that the body can get used to these tablets so that they no longer work properly. If you stop taking the tablets suddenly, there may be unpleasant withdrawal effects which you will experience. Research work done in this field shows that repeated use of the tablets over a long time is no longer recommended. More importantly, these tablets may actually cause anxiety and sleeplessness and they can be addictive.

I am writing to ask you to consider cutting down on your dose of these tablets and perhaps stopping them at some time in the future. The best way to do this is to take the tablets only when you feel they are absolutely necessary. Try to take them only when you know that you have to do something that might be difficult for you. In this way you might be able to make a prescription last longer.

Once you have begun to cut down, you might be able to think about stopping them altogether. It would be best to cut down very gradually and then you will be less likely to have withdrawal symptoms.

If you would like to talk to me personally about this, I would be delighted to see you in the surgery whenever it is convenient for you to attend

Yours sincerely

References

- Department of Health. Health and personal social services statistics for England. London: HMSO, 1991.
- Williams P, Bellantuono C. Long-term tranquilliser use: the contribution of epidemiology. In: Gabe J (ed). Understanding tranquilliser use. London: Routledge, 1991.
- Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988; 296: 603-606.
- Dunbar GC, Perera MH, Jenner FA. Patterns of benzodiazepine use in Great Britain as measured by a general population survey.

- Morgan K. Sedative-hypnotic drug use and ageing. Arch Gerontol Geriatr 1983; 2: 181-199.
- Ashton H, Golding JF. Tranquillisers: prevalence, predictors and possible consequences. Data from a large United Kingdom survey. Br J Addition 1989: 84: 541-546.
- Parry HJ, Balter MB, Mellinger GD, et al. National patterns of psychotherapeutic drug use. Arch Gen Psychiatry 1973; 28: 769-783.
- Lader MH, Ron M, Petursson H. Computed axial brain tomography in long-term benzodiazepine users. Psychol Med 1984; 14: 203-206
- 23. Russell MAH, Wilson C, Taylor C, Baker CD. Effect of general
- practitoners' advice against smoking. BMJ 1979; 2: 231.
 24. Balint M. The doctor, his patient and the illness. London: Pitman,
- Ramsden RT. Balance disorders in the elderly. Med Dialogue 1992;

Acknowledgements

The study was funded by a grant from the Devon Northcott Medical Foundation and by a contribution from the Department of Clinical and Community Psychology, Exeter Health Authority, Rachel Kirby gave computer expertise, Sandy Salisbury provided secretarial services, Karen Jackson typed the various stages of the manuscript, Stuart Brooks helped in the initial programming of the database and Ann-Marie Corner assisted in the data entry onto the computer. The University of Exeter Departments of Psychology and General Practice collaborated on this joint venture and encouraged the development of the research. The doctors in the study took part in the planning and design stages and we would like to thank them and their practice staff for their continuing help in the data collection.

Address for correspondence

Dr M A Cormack, Wessex Regional Training Course in Clinical Psychology, Knowle Hospital, Fareham, Hampshire PO17 5NA.

RCGP Publications OCCASIONAL PAPERS

58 CLINICAL GUIDELINES - REPORT OF A LOCAL INITIATIVE

£11.00

These clinical guidelines, originally developed for local use by the Department of Primary Health Care and known as the Islington Guidelines, have been extensively revised to make them applicable nationwide. Includes chapters on recommended guidelines on common medical conditions, preventive



Mugunthan et al., 2011: A meta-analysis showing that letter-only intervention can be effective in reducing benzodiazepine prescribing, no evidence to suggest follow up consultations offer any additional support https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162180/



- Discussed the results of the search at the next clinical meeting, and discussed some of the papers I had found
- We decided at the meeting to:
 - New patients:
 - We created a letter of Sleep Hygiene advice in SystmOne to make it easier for clinicians to print/send during consultations
 - Update on CBT, LIFT Psychology courses where sleep hygiene measures fail
 - Agreed new prescriptions would be restricted to 7 days, advice to avoid using more than twice a week and <4 weeks.
 - Existing patient
 - Adapted the letter from Cormack et al, 1994 and sent this to patients identified in our search
 - Review Hypnotics on quarterly report

10 tips to beat insomnia.

Simple lifestyle changes can make a world of difference to your quality of sleep Follow these 10 tips for a more restful night.

1. Keep regular sleep hours

Going to bed and getting up at roughly the same time every day will programme your body to sleep better. Choose a time when you're likely to feel tired and sleepy.

2. Create a restful sleeping environment

Your bedroom should be a peaceful place for rest and sleep. Temperature, lighting and noise should be controlled so that your bedroom environment helps you to fall (and stay) asleep. If you have a pet that sleeps in the room with you, consider moving it somewhere else if it often disturbs you

3. Make sure your bed is comfortable

It's difficult to get restful sleep on a mattress that's too soft or too hard, or a bed that's too small or old.

Moderate exercise on a regular basis, such as swimming or walking, can help relieve some of the tension built up over the day. But make sure you do not do vigorous exercise, such as running or the gym, too close to bedtime, as it may keep you awake.

Find out more about how to get active your way.

Cut down on caffeine

Cut down on caffeine in tea, coffee, energy drinks or colas, especially in the evening. Caffeine interferes with the process of falling asleep, and also prevents deep sleep. Instead, have a warm, milky drink or herbal tea.







Courses V What's on your mind V What Do We Offer V Physical Health V About Us V

This free, four-week course aims to help people experiencing sleep difficulties (not sleeping enough / disrupted sleep / early morning waking), who are also experiencing any other condition, whether physical or emotional in nature. The course aims to help you understand your sleep difficulties and provide you wit

techniques which can help you cope with poor sleep

Overcoming Sleep Difficulties

· Understanding theories of sleep and what happens in the body when we slee

Thanks for listening!



